The study included 421 patients and utilized the AMIStem system for minimally invasive total hip replacements. Here are five key findings:
1. The five-year survival rate for the AMIStem was 97.75 percent.
2. The implant scored a 5A rating from the ODEP, putting it on track to have outcomes in-line with the 10A rating, which requires a 10-year follow-up.
3. The AMIStem has been used more than 100,000 times and the technique has been performed more than 200,000 times.
4. Medacta’s M.O.R.E Educational Platform supports the technology and found more than 85 percent of the company’s hip replacement surgeries are now performed through AMIS.
5. The researchers in the study concluded the technology is a “safe and reliable solution” for cementless hip arthroplasty.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
